SOCS5 and postmenopausal osteoporosis: in vitro: - Inhibition of cell viability and promotion of lactate dehydrogenase release, increasing the RANKL/OPG ratio and decreasing Runx2 and BMP2 expressions;in vivo:- In an ovariectomized rat model, miR-151a-3p decreased bone mineral density and biomechanical parameters of femurs, targeting SOCS5;- miR-151a-3p contributes to the pathogenesis of postmenopausal osteoporosis and promotes its progress;